ERBB2 and breast carcinoma: Because CXCR4 is expressed in all subtypes and to the highest degree in TNBCs [20], breast cancer patients who do not benefit from hormonal or anti-HER-2 therapy may potentially benefit from CXCR4 targeted therapies.